Optimal bacteriophage mutation rates for phage therapy
- PMID: 17904162
- DOI: 10.1016/j.jtbi.2007.08.007
Optimal bacteriophage mutation rates for phage therapy
Abstract
The mutability of bacteriophages offers a particular advantage in the treatment of bacterial infections not afforded by other antimicrobial therapies. When phage-resistant bacteria emerge, mutation may generate phage capable of exploiting and thus limiting population expansion among these emergent types. However, while mutation potentially generates beneficial variants, it also contributes to a genetic load of deleterious mutations. Here, we model the influence of varying phage mutation rate on the efficacy of phage therapy. All else being equal, phage types with historical mutation rates of approximately 0.1 deleterious mutations per genome per generation offer a reasonable balance between beneficial mutational diversity and deleterious mutational load. We determine that increasing phage inoculum density can undesirably increase the peak density of a mutant bacterial class by limiting the in situ production of mutant phage variants. For phage populations with minimal genetic load, engineering mutation rate increases beyond the mutation-selection balance optimum may provide even greater protection against emergent bacterial types, but only with very weak selective coefficients for de novo deleterious mutations (below approximately 0.01). Increases to the mutation rate beyond the optimal value at mutation-selection balance may therefore prove generally undesirable.
Similar articles
-
Coevolution with viruses drives the evolution of bacterial mutation rates.Nature. 2007 Dec 13;450(7172):1079-81. doi: 10.1038/nature06350. Epub 2007 Dec 2. Nature. 2007. PMID: 18059461
-
Contamination of the genome by very slightly deleterious mutations: why have we not died 100 times over?J Theor Biol. 1995 Aug 21;175(4):583-94. doi: 10.1006/jtbi.1995.0167. J Theor Biol. 1995. PMID: 7475094
-
Viruses versus bacteria-novel approaches to phage therapy as a tool against multidrug-resistant pathogens.J Antimicrob Chemother. 2014 Sep;69(9):2326-36. doi: 10.1093/jac/dku173. Epub 2014 May 28. J Antimicrob Chemother. 2014. PMID: 24872344 Review.
-
Phage cocktails and the future of phage therapy.Future Microbiol. 2013 Jun;8(6):769-83. doi: 10.2217/fmb.13.47. Future Microbiol. 2013. PMID: 23701332 Review.
-
[Selection and properties of totally phage-resistant mutant Pseudomonas putida PpG1].Genetika. 1996 Mar;32(3):348-53. Genetika. 1996. PMID: 8723627 Russian.
Cited by
-
Dynamics of immune memory and learning in bacterial communities.Elife. 2023 Jan 16;12:e81692. doi: 10.7554/eLife.81692. Elife. 2023. PMID: 36645771 Free PMC article.
-
Back to the future: evolving bacteriophages to increase their effectiveness against the pathogen Pseudomonas aeruginosa PAO1.Evol Appl. 2013 Nov;6(7):1054-63. doi: 10.1111/eva.12085. Epub 2013 Jul 15. Evol Appl. 2013. PMID: 24187587 Free PMC article.
-
How does feedback from phage infections influence the evolution of phase variation in Campylobacter?PLoS Comput Biol. 2021 Jun 14;17(6):e1009067. doi: 10.1371/journal.pcbi.1009067. eCollection 2021 Jun. PLoS Comput Biol. 2021. PMID: 34125841 Free PMC article.
-
Automating Predictive Phage Therapy Pharmacology.Antibiotics (Basel). 2023 Sep 8;12(9):1423. doi: 10.3390/antibiotics12091423. Antibiotics (Basel). 2023. PMID: 37760719 Free PMC article. Review.
-
A Review of Using Mathematical Modeling to Improve Our Understanding of Bacteriophage, Bacteria, and Eukaryotic Interactions.Front Microbiol. 2021 Sep 21;12:724767. doi: 10.3389/fmicb.2021.724767. eCollection 2021. Front Microbiol. 2021. PMID: 34621252 Free PMC article. Review.
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Medical